Interim report from burden of obstructive lung disease (bold study) in tehran: Prevalence and risk factors of chronic obstructive pulmonary disease

Hooman Sharifi, Mohammad Reza Masjedi, Habib Emami, Mostafa Ghanei, Alireza Eslaminejad, Golnar Radmand, A (Sonia) Buist

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Chronic Obstructive Pulmonary Diseases (COPD) is estimated to rank fifth in burden of disease and third in terms of mortality by 2020 worldwide. It is characterized by chronic inflammation and non-fully reversible airflow obstruction, causing structural changes in the lungs that can be demonstrated by a post bronchodilator FEV1/FVC ratio

Original languageEnglish (US)
Pages (from-to)6-13
Number of pages8
JournalTanaffos
Volume13
Issue number3
StatePublished - 2014

Fingerprint

Obstructive Lung Diseases
Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Inflammation
Lung
Mortality

Keywords

  • Chronic obstructive pulmonary disease
  • COPD
  • Iran
  • Symptoms

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Interim report from burden of obstructive lung disease (bold study) in tehran : Prevalence and risk factors of chronic obstructive pulmonary disease. / Sharifi, Hooman; Masjedi, Mohammad Reza; Emami, Habib; Ghanei, Mostafa; Eslaminejad, Alireza; Radmand, Golnar; Buist, A (Sonia).

In: Tanaffos, Vol. 13, No. 3, 2014, p. 6-13.

Research output: Contribution to journalArticle

Sharifi, Hooman ; Masjedi, Mohammad Reza ; Emami, Habib ; Ghanei, Mostafa ; Eslaminejad, Alireza ; Radmand, Golnar ; Buist, A (Sonia). / Interim report from burden of obstructive lung disease (bold study) in tehran : Prevalence and risk factors of chronic obstructive pulmonary disease. In: Tanaffos. 2014 ; Vol. 13, No. 3. pp. 6-13.
@article{01acb023f3b4496fa0c34c18d479ed4e,
title = "Interim report from burden of obstructive lung disease (bold study) in tehran: Prevalence and risk factors of chronic obstructive pulmonary disease",
abstract = "Background: Chronic Obstructive Pulmonary Diseases (COPD) is estimated to rank fifth in burden of disease and third in terms of mortality by 2020 worldwide. It is characterized by chronic inflammation and non-fully reversible airflow obstruction, causing structural changes in the lungs that can be demonstrated by a post bronchodilator FEV1/FVC ratio",
keywords = "Chronic obstructive pulmonary disease, COPD, Iran, Symptoms",
author = "Hooman Sharifi and Masjedi, {Mohammad Reza} and Habib Emami and Mostafa Ghanei and Alireza Eslaminejad and Golnar Radmand and Buist, {A (Sonia)}",
year = "2014",
language = "English (US)",
volume = "13",
pages = "6--13",
journal = "Tanaffos",
issn = "1735-0344",
publisher = "Shaheed Beheshti University of Medical Sciences and Health Services",
number = "3",

}

TY - JOUR

T1 - Interim report from burden of obstructive lung disease (bold study) in tehran

T2 - Prevalence and risk factors of chronic obstructive pulmonary disease

AU - Sharifi, Hooman

AU - Masjedi, Mohammad Reza

AU - Emami, Habib

AU - Ghanei, Mostafa

AU - Eslaminejad, Alireza

AU - Radmand, Golnar

AU - Buist, A (Sonia)

PY - 2014

Y1 - 2014

N2 - Background: Chronic Obstructive Pulmonary Diseases (COPD) is estimated to rank fifth in burden of disease and third in terms of mortality by 2020 worldwide. It is characterized by chronic inflammation and non-fully reversible airflow obstruction, causing structural changes in the lungs that can be demonstrated by a post bronchodilator FEV1/FVC ratio

AB - Background: Chronic Obstructive Pulmonary Diseases (COPD) is estimated to rank fifth in burden of disease and third in terms of mortality by 2020 worldwide. It is characterized by chronic inflammation and non-fully reversible airflow obstruction, causing structural changes in the lungs that can be demonstrated by a post bronchodilator FEV1/FVC ratio

KW - Chronic obstructive pulmonary disease

KW - COPD

KW - Iran

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=84922382414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922382414&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84922382414

VL - 13

SP - 6

EP - 13

JO - Tanaffos

JF - Tanaffos

SN - 1735-0344

IS - 3

ER -